Ibrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation
Yu. E. Ryabukhina,
P. A. Zeynalova,
O. L. Timofeeva,
F. M. Abbasbeyli,
T. T. Valiev,
A. G. Zhukov,
V. V. Fedotov https://doi.org/10.17650/2782-3202-2023-3-3-18-28
Abstract
Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder which despite achieved successes in therapy is characterized by recurrences and refractoriness. Study of molecular biology allowed to use targeted drugs, in particular ibrutinib which acts through suppression of B cell receptor signaling pathway by inhibiting Bruton’s tyrosine kinase. In several large trials, ibrutinib demonstrated its effectiveness and manageable toxicity profile both in patients with newly diagnosed and recurrent/refractory WM. A clinical observation of a patient with WM is presented. Due to minimal response during previous treatment, the patient currently is undergoing monotherapy with ibrutinib with positive antitumor effect, satisfactory tolerability, and absence of significant adverse events. The effect of ibrutinib on humoral immunity during the follow up period was evaluated.
Keywords
Waldenstrom’s macroglobulinemia,
B-cell lymphoproliferative disorder,
ibrutinib,
Bruton’s tyrosine kinase inhibitor
Supporting agencies: The work was performed without external funding
About the Authors
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Yulia Evgenyevna Ryabukhina
143081
111 1st Uspenskoe Shosse
Moscow region
Lapino
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
143081
111 1st Uspenskoe Shosse
119991
Bld. 2, 8 Trubetskaya St.
Moscow region
Lapino
Moscow
O. L. Timofeeva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081
111 1st Uspenskoe Shosse
Moscow region
Lapino
F. M. Abbasbeyli
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081
111 1st Uspenskoe Shosse
Moscow region
Lapino
T. T. Valiev
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
119991
Bld. 2, 8 Trubetskaya St.
Moscow
A. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081
111 1st Uspenskoe Shosse
Moscow region
Lapino
V. V. Fedotov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; YUNIM”, LLC
Russian Federation
Russian Federation
143081
111 1st Uspenskoe Shosse
121205
0.049 office 1st core, Bld. 1, 42 Bolshoy Bvd., Skolkovo Innovation Center
Moscow region
Lapino
Moscow
References
1. Hematology: National guidelines. Ed. by O.A. Rukavitsyn. Moscow: GEOTAR -Media, 2017. 784 p.
2. Gertz M.A. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 2021;96(2):258–69. DOI: 10.1002/ajh.26082
3. Stone M.J. Waldenström’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 2009;9(1):97–9. DOI: 10.3816/CLM.2009.n.026
4. Baehring J.M., Hochberg E.P., Raje N. et al. Neurological manifestations of Waldenström macroglobulinemia. Nat Clin Pract Neurol 2008;4(10): 547–56. DOI: 10.1038/ncpneuro0917
5. Ghobrial I.M., Uslan D.Z., Call T.G. et al. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol 2004;77(4):329–30. DOI: 10.1002/ajh.20207
6. Berentsen S. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009;9(1):110–2. DOI: 10.3816/CLM.2009.n.030
7. Walsh S.H., Laurell A., Sundström G. et al. Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia derives from an extensively hypermutated B cell that lacks on going somatic hypermutation. Leuk Res 2005;29(7):729–34. DOI: 10.1016/j.leukres.2004.12.008
8. Stone M.J., Pascual V. Pathophysiology of Waldenström’s macroglobulinemia. Haematologica 2010;95(3):359–64. DOI: 10.3324/haematol.2009.017251
9. Treon S.P., Xu L., Yang G. et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 2012;367(9):826–33. DOI: 10.1056/NEJMoa1200710
10. Treon S.P., Xu L., Guerrera M.L. et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol 2020;38(11):1198–208. DOI: 10.1200/JCO.19.02314
11. Yang G., Zhou Y., Liu X. et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013;122(7):1222–32. DOI: 10.1182/blood-2012-12-475111
12. Advani P., Paulus A., Ailawadhi S. Updates in prognostication and treatment of Waldenström’s macroglobulinemia. Hematol Oncol Stem Cell Ther 2019;12(4):179–88. DOI: 10.1016/j.hemonc.2019.05.002
13. Varettoni M., Zibellini S., Arcaini L. et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 2013;122(13):2284–5. DOI: 10.1182/blood-2013-07-513366
14. Kyle R.A., Therneau T.M., Rajkumar S.V. et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102(10):3759–64. DOI: 10.1182/blood-2003-03-0801
15. Sun H., Fang T., Wang T. et al. Single-cell profles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia. J Transl Med 2022;20(1):576. DOI: 10.1186/s12967-022-03798-6
16. Clinical recommendations. Waldenstrom’s macroglobulinemia. Association of Oncologists of Russia, 2020. 41 p.
17. NCCN Guidelines. Version 1.2023. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma.
18. Rummel M.J., Niederle N., Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203–10. DOI: 10.1016/S0140-6736(12)61763-2
19. Rummel M., Lerchenmüller C., Hensel M. et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with Waldenström’s macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). Blood 2019;134(Supplement_1):343. DOI: 10.1182/blood-2019-121909
20. Treon S.P., Ioakimidis L., Soumerai J.D. et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27(23):3830–5. DOI: 10.1200/JCO.2008.20.4677
21. Tedeschi A., Benevolo G., Varettoni M. et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;118(2):434–43. DOI: 10.1002/cncr.26303
22. Dimopoulos M.A., Kastritis E., Owen R.G. et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014;124(9):1404–11. DOI: 10.1182/blood-2014-03-565135
23. Advani R.H., Buggy J.J., Sharman J.P. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88–94. DOI: 10.1200/JCO.2012.42.7906
24. Castillo J.J., Meid K., Gustine J.N. et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenström macroglobulinemia. Leukemia 2022;36(2):532–9. DOI: 10.1038/s41375-021-01417-9
25. Dimopoulos M.A., Tedeschi A., Trotman J. et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 2018;378(25):2399–410. DOI: 10.1056/NEJMoa1802917
26. Treon S.P., Tripsas C.K., Meid K. et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372(15):1430–40. DOI: 10.1056/NEJMoa1501548
27. Treon S.P., Meid K., Gustine J. et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol 2021;39(6):565–75. DOI: 10.1200/JCO.20.00555
28. Cencini E., Romano I., Ghio F. et al. Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: areal-life, retrospective study on behalf of the “RT L” (regional Tuscan lymphoma network). Ann Hematol 2023;102(4):841–9. DOI: 10.1007/s00277-023-05113-9
29. Owen R.G., Kyle R.A., Stone M.J. et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160(2):171–6. DOI: 10.1111/bjh.12102
30. Sun C., Tian X., Lee Y.S. et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015;126(19):2213–9. DOI: 10.1182/blood-2015-04-639203
31. Byrd J.C., Furman R.R., Coutre S.E. et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32–42. DOI: 10.1056/NEJMoa1215637
32. Buske C., Jurczak W., Salem J.E., Dimopoulos M.A. Managing Waldenström’s macroglobulinemia with BTK inhibitors. Leukemia 2023;37(1):35–46. DOI: 10.1038/s41375-022-01732-9
Review
For citations:
Ryabukhina Yu.E., Zeynalova P.A., Timofeeva O.L., Abbasbeyli F.M., Valiev T.T., Zhukov A.G., Fedotov V.V. Ibrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation. MD-Onco. 2023;3(3):18-28. (In Russ.) https://doi.org/10.17650/2782-3202-2023-3-3-18-28
Views:
467
Email this article 